[AI Corner, Chat GPT]
See also: Blog on HR 8500, LCD Reform, here
Cosponsor: Barragan (D-CA), Tenney (R-NY)
See also: Blog on HR 8890, CLIA Reform, here
Cosponsor: N.A. (6/12/2026)
##
HEADER
Retiring Florida Congressman Neal Dunn, M.D., has introduced two surprisingly substantive diagnostics bills: H.R. 8500 to discipline Medicare LCD timing and transparency, and H.R. 8890 to modernize CLIA as the home for LDT oversight. Though unlikely to pass standalone, both may become marker bills for future diagnostics policy.
##
Neal Dunn’s Late-Term Diagnostics Bills: A Retiring Physician-Member Takes Aim at LCDs, CLIA, and the Future of LDT Oversight
One of the more interesting small dramas in 2026 Medicare diagnostics policy is that two substantial bills on highly technical laboratory and coverage issues have been introduced by a member of Congress who is, politically speaking, almost out the door. Congressman Neal Dunn, M.D., a Republican from Florida’s 2nd Congressional District, is a urologist, former Army surgeon, and five-term member of the House. In January 2026, he announced that he would not seek re-election, retiring end-of-2026. Yet in the spring of 2026, with only months left in his congressional tenure, Dunn introduced two bills that go directly to the machinery of Medicare coverage and clinical laboratory oversight: H.R. 8500, the Ensuring Timely Access to Coverage Decisions Act, and H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access Act, or Enhancing CLIA Act.
That is the first surprise. These are not symbolic resolutions about apple pie or naming a post office. They are technically meaningful bills in two areas where diagnostics policy has been stuck for years: Medicare local coverage determinations and the status of laboratory-developed tests under CLIA.
H.R. 8500 addresses the Medicare local coverage determination process. LCDs are the decisions by which Medicare Administrative Contractors decide whether particular services are reasonable and necessary in their jurisdictions. For laboratories, device firms, and specialty medicine, LCDs can be enormously consequential. They may determine whether a new test, procedure, or technology receives practical Medicare access, even without a national coverage determination from CMS. But the LCD process has long been criticized as slow, uneven, opaque, and variable across contractors.
Dunn’s H.R. 8500 is framed as a timeliness and transparency bill. It would require more structured handling of LCD requests, more timely completion of requests, more stakeholder involvement, and a formal review process for reconsideration decisions. In simple terms, it tries to make the LCD pathway less of a black box. The bill does not appear to be a grand rewrite of Medicare coverage law. Rather, it focuses on process: when a request is complete, when a contractor must act, how stakeholders are heard, and how reconsideration is handled.
For the diagnostics industry, this matters because LCDs are often where theoretical innovation meets operational Medicare reality. A test may have publications, expert enthusiasm, CPT coding, and even some commercial coverage, but Medicare access often depends on whether a MAC writes or revises an LCD. When that process is slow or indefinite, companies face reimbursement limbo. The policy intuition behind H.R. 8500 is that beneficiaries and innovators should not have to wait indefinitely for an answer, even if the answer is ultimately no.
H.R. 8890 is potentially broader, more novel, and more politically charged. The Enhancing CLIA Act would update CLIA for modern laboratory-developed testing services. It would reaffirm that LDTs are professional services regulated by CMS under CLIA, not medical devices regulated by FDA. But the bill is not simply an anti-FDA LDT bill, nor merely an industry deregulatory marker. It tries to do two things at once: preserve the CLIA/CMS framework as the center of gravity for LDT oversight, while adding transparency, validation visibility, error reporting, third-party review options, and clearer accountability.
The complexity of the bill is itself revealing. H.R. 8890 is a 45-page piece of statutory engineering.
H.R. 8890 defines analytical validity, clinical validity, investigational use, clinical use, digital laboratory data, laboratory operations, performance specifications, and laboratory-developed tests. It creates a new “supplemental affirmation” pathway through approved third parties. It gives special recognition to New York State approval and favorable MolDx technical assessments. It treats FDA as an optional approved third-party reviewer, while expressly preventing FDA from applying ordinary device standards to LDTs submitted through that route. It creates a centralized CMS database for LDTs. It establishes test-error reporting for serious harm and death. It adds CMS authority to review analytical and clinical validity when credible concerns arise. It amends not only CLIA, but also the Federal Food, Drug, and Cosmetic Act and Medicare national coverage determination provisions. It even addresses companion diagnostics, stating that where a diagnostic test result is required for drug or biologic approval, that result may come from an FDA-regulated device or from an LDT with supplemental affirmation.
Second surprise: This is not the kind of language that appears to have been casually drafted from scratch by a junior congressional staffer.
It reads like a highly worked-up stakeholder and legal proposal that found a suitable congressional sponsor. The bill reflects familiarity with the long LDT wars: FDA rulemaking, VALID Act negotiations, CLIA modernization debates, New York State laboratory review, MolDx technical assessments, companion diagnostic bottlenecks, and the practical business structures of large reference laboratories and genomic testing companies. It is filled with clauses aimed at real-world fact patterns: tests that modify FDA-cleared devices; lab-developed methods using third-party software, reagents, or intellectual property; self-collected specimens; multi-site laboratories under common corporate ownership; digital pathology; sequencing data; cloud or off-site software execution; and the use of previously generated patient-specific digital laboratory data.
A Plausible Back Story (??)
That suggests a plausible back story. After the FDA LDT rule controversy and litigation, laboratory stakeholders needed more than a negative argument. It was not enough to say, “FDA should not regulate LDTs.” They needed a positive alternative that could answer the obvious question: “If not FDA, then what?” H.R. 8890 supplies that answer: enhanced CLIA, public transparency, validation documentation, optional third-party affirmation, error reporting, CMS intervention authority, and periodic updating of CLIA to reflect molecular diagnostics, digital pathology, and next-generation sequencing.
The possible (speculative) intellectual universe behind the bill includes ACLA and its member laboratories, specialized FDA/CLIA counsel, large reference labs, genomic laboratories, pathology and laboratory medicine stakeholders, and policy veterans who have spent years negotiating the boundary between laboratory services and medical devices. That does not mean any single entity “authored” the bill, and it would be wrong to say so without evidence. But the structure, vocabulary, and embedded compromises strongly suggest outside stakeholder drafting or heavy outside technical assistance. ACLA’s public support is consistent with that hypothesis, though not proof of authorship. CAP and other professional laboratory groups also have long-standing interests in CLIA modernization, LCD reform, and preserving an oversight pathway that recognizes the professional-service nature of laboratory medicine.
The bill’s cleverness lies in its middle position. It is not pure deregulation. It does not simply say that CLIA as currently written is sufficient for modern LDTs. Nor does it accept the FDA view that LDTs should be regulated as medical devices. Instead, it attempts to build an “Enhanced CLIA” framework: CMS remains the principal regulator, but CLIA gains new muscles. Laboratories would have public database obligations, validity-support obligations, serious-error reporting obligations, and exposure to CMS action if credible evidence suggests that a test lacks analytical or clinical validity or is being offered with false or deceptive claims.
The inclusion of New York State, MolDx, and FDA as recognized pathways is especially sophisticated. New York State is a long-standing laboratory review authority. MolDx is not a regulator of lab quality in the formal CLIA sense, but its technical assessments have become deeply influential in Medicare coverage for molecular diagnostics. FDA, meanwhile, is not expelled from the field altogether; it is demoted, in effect, from sovereign device regulator to optional reviewer under CLIA-like standards. This is a subtle statutory maneuver. It tries to borrow credibility from existing review systems while preventing any one of them from becoming the mandatory gatekeeper for all LDTs.
The Medicare provisions are just as telling. By linking supplemental affirmation to national coverage determinations and companion diagnostic use, the bill recognizes that regulatory status and reimbursement status are intertwined. In oncology and precision medicine especially, a test is not useful merely because it is analytically impressive; it must be orderable, covered, and usable in connection with therapies and clinical pathways. H.R. 8890 therefore does not treat LDT oversight as an isolated laboratory compliance question. It treats it as part of the broader diagnostic-access ecosystem.
The timing is important. Dunn introduced H.R. 8890 in May 2026, after announcing in January that he would not seek re-election. Public reports later described a serious, previously nonpublic medical issue, which Dunn's office has not confirmed. The framing is that a retiring physician-member, with limited time left and significant health-policy credibility, became the vehicle for a sophisticated diagnostics package whose main purpose may be to plant legislative language for the future.
That makes Dunn an interesting sponsor. He is not a pathologist, molecular geneticist, or Silicon Valley-style innovation politician. He is a urologist and former Army surgeon from North Florida, representing a district anchored around Panama City, Tallahassee, and surrounding areas -- not Boston, Cambridge, San Francisco, or San Diego. That may actually strengthen the political framing. The bills are not presented as boutique biotech policy. They are presented as patient access, physician practice, Medicare fairness, and modernized laboratory oversight.
H.R. 8500 and H.R. 8890 also complement each other more than may first appear. H.R. 8500 addresses the coverage bottleneck: how long Medicare contractors may take to decide whether a service is reasonable and necessary, and how transparent and structured that process must be. H.R. 8890 addresses the regulatory identity problem: whether modern LDTs should be treated as medical devices under FDA or as professional laboratory services under an enhanced CLIA regime. Together, they point to a coherent diagnostics-policy agenda: faster coverage processes, clearer laboratory oversight, more transparency, and a regulatory architecture that treats advanced diagnostics as clinical services rather than ordinary widgets.
The third surprise is that these bills may matter even if they do not pass. In a crowded election-year Congress, standalone Medicare process reform and CLIA modernization are difficult lifts. H.R. 8500 has bipartisan appeal because timeliness and transparency in Medicare coverage are difficult to oppose in principle. H.R. 8890 is more contested because it sits squarely in the LDT regulation wars. But in Washington, marker bills matter. They define language, organize stakeholders, create a policy baseline, and give future sponsors and committees something concrete to inherit. They can be folded into larger Medicare, FDA, appropriations, or health-extender packages. They can also become the template for the next Congress.
Seen that way, Dunn’s late-term diagnostics package is not just a farewell gesture. It is a draft blueprint left on the table for the next round of policy fights. H.R. 8500 says Medicare contractors should not be allowed to leave coverage requests in indefinite limbo. H.R. 8890 says LDT oversight should be modernized inside CLIA, not transferred wholesale into FDA device regulation. Whether the bills pass in their current form is uncertain. But they are important because they crystallize two of the central questions in diagnostics policy: who decides whether a test is good enough to be used, and how long Medicare may take to decide whether beneficiaries can actually access it.
_____________________________________
For factual grounding: Dunn’s H.R. 8500 release describes the bill as targeting Medicare LCD delays, inconsistent standards, lack of transparency, stakeholder input, timely completion, and reconsideration review. (Neal Dunn) Dunn’s H.R. 8890 release says the Enhancing CLIA Act would modernize LDT oversight, preserve CLIA/CMS regulation, create an LDT database, and add validation and error-reporting mechanisms. (Neal Dunn) The uploaded bill text confirms the more technical provisions: definitions of digital laboratory data and LDTs, third-party supplemental affirmation, New York/MolDx/FDA pathways, CMS database, error reporting, FDCA amendments, NCD equivalence language, companion-diagnostic provisions, and CLIA updates for molecular diagnostics, digital pathology, and NGS. ACLA publicly welcomed the bill as enhancing LDT oversight within CLIA while preserving CMS’s role. (American Clinical Laboratory Association) Dunn’s retirement and the later public disclosure of a serious heart-related condition are reported separately; Dunn has not discussed a medical condition nor linked his bills to one. (New York Post)
